idarucizumab

01/01/2020 - "Among patients with major bleeding (n = 57), treatment with idarucizumab was considered effective in 44 (77.2%) of them. "
04/01/2022 - "Idarucizumab administration immediately improved both bleeding and renal parameters. "
01/01/2019 - "Idarucizumab helped achieve haemostasis in 15 bleeding patients and allowed 6 patients to undergo urgent surgery. "
01/01/2016 - "Another randomized clinical trial assessed the safety and efficacy of idarucizumab in patients with either overt bleeding or undergoing emergency surgery where hemostasis was required. "
10/17/2023 - "This multicenter, open-label, uncontrolled, non-interventional PMS study was conducted in Japanese patients who received idarucizumab at the approved dose (2 × 2.5 g/50 ml) and had uncontrolled bleeding (group A) or required an emergency procedure (group B). "

05/04/2023 - "Conclusions: Our study demonstrated the real-world effectiveness and safety of idarucizumab infusion for trial-eligible patients and all acute ischemic stroke patients. "
09/27/2022 - "Further randomized controlled trials should be performed to evaluate the safety and effectiveness of idarucizumab for acute ischemic stroke treatment."
04/01/2020 - "The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA."
01/01/2020 - "Among patients suspected of ischemic stroke, Idarucizumab, may be administered preceding thrombolysis. "
11/15/2018 - "Idarucizumab-facilitated intravenous thrombolysis in acute ischemic stroke: A therapeutic strategy requiring further investigation."

04/01/2021 - "Idarucizumab in major trauma patients: a single centre real life experience."
01/01/2017 - "On day 4, animals were randomised 1:1:1 to receive idarucizumab 60+0, 60+60 or 120+0 mg/kg. Doses were administered 15 and 75 minutes after initial liver trauma. "
01/01/2017 - "At sufficient doses, idarucizumab rapidly reduced blood loss and improved survival in this lethal porcine model of double trauma with dabigatran anticoagulation. "
08/06/2021 - "Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients."
01/01/2017 - "It was the aim of this study to investigate the effect of idarucizumab, given once or as a split dose, after double trauma in pigs anticoagulated with dabigatran. "

01/01/2021 - "Real-life studies strongly support the benefits of idarucizumab availability in stroke units and emergency departments."
09/27/2022 - "Materials and Methods: We included the data of nine idarucizumab-treated patients from the Riga East University Hospital Stroke Registry from 2018 to 2022 in our retrospective medical records analysis. "
12/01/2020 - "Over the same 24-month period, 386 patients had stroke clot retrieval, of whom 8 (2.1%) were first treated with idarucizumab. "
01/01/2020 - "In patients receiving intravenous thrombolysis with rt-PA following idarucizumab, 78% showed a median improvement of 7 points in National Institutes of Health Stroke Scale. "
01/01/2020 - "One-hundred and twenty stroke patients received idarucizumab in 61 stroke centers. "

02/01/2019 - "In total, 13 patients received idarucizumab for atrial fibrillation during the study period. "
08/01/2023 - "In this report, we present a case of a 66-year-old male with atrial fibrillation treated with dabigatran who received idarucizumab prior to orthotopic liver transplantation. "
01/01/2022 - "Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2."
01/01/2022 - "Therefore, further reporting on this is needed and neuroradiographic correlation may help validate this concept. At our hospital in Tampa, Florida, two octogenarians with atrial fibrillation, adherent with the DOAC dabigatran, presented with AIS shortly after symptom onset. Both received idarucizumab, then IVT. Clinical outcomes, treatment times, and perfusion-based neuroradiographic parameters were assessed. "
08/21/2019 - "Idarucizumab was used preoperatively to reverse the effects of dabigatran, which he was taking for chronic atrial fibrillation. "